NCM
LVTX

Nantahala Capital Management’s LAVA Therapeutics LVTX Stock Holding History

Nantahala Capital Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-322,980
Closed -$953K – 129
2022
Q2 		$953K Sell
322,980
-11,184
-3% -$38.8K 0.05% 95
2022
Q1 		$1.47M Sell
334,164
-26,644
-7% -$135K 0.07% 95
2021
Q4 		$1.98M Sell
360,808
-8,482
-2% -$55.6K 0.07% 107
2021
Q3 		$2.19M Sell
369,290
-11,937
-3% -$85.9K 0.07% 103
2021
Q2 		$4.15M Hold
381,227
– – 0.12% 95
2021
Q1 		$5.79M Buy
+381,227
New +$5.24M 0.17% 78

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nantahala Capital Management's LVTX Position: Q3 2022 in Review

Nantahala Capital Management sold out of LAVA Therapeutics (LVTX) in Q3 2022, closing a stake of 322,980 shares — an estimated $953K sold.

Nantahala Capital Management first reported a position in LVTX in Q1 2021 and held it in 6 quarters. The position peaked at $5.79M in Q1 2021. 13 funds tracked by Wall St. Rank hold LVTX as of Q3 2022.

  • Nantahala Capital Management reported no remaining LAVA Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Nantahala Capital Management sold 322,980 LAVA Therapeutics shares in Q3 2022, an estimated $953K.
  • Nantahala Capital Management first reported a position in LAVA Therapeutics in Q1 2021 and held it in 6 quarters.
  • Nantahala Capital Management's LAVA Therapeutics position peaked at $5.79M in Q1 2021.
  • 13 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2022.

Based on Nantahala Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.